Search research articles
Contact Us
Filters
Showing results (41-50 of 78) with videos related to
Page
of 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 26, 2023
Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
Bachchu Lal, Aditya Kulkarni, Joseph McDermott, et al.
Scientific Reports
|
May 24, 2018
The Diversity of Chemoprotective Glucosinolates in Moringaceae (Moringa spp.)
Jed W Fahey, Mark E Olson, Katherine K Stephenson, et al.
Journal of Medicinal Chemistry
|
March 21, 2019
Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs
Lukáš Tenora, Jesse Alt, Ranjeet P Dash, et al.
Theranostics
|
June 3, 2020
Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome
Elizabeth Smith Khoury, Anjali Sharma, Rajasekhar R Ramireddy, et al.
Nature Communications
|
November 17, 2023
Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis
Sadiya Parveen, Jessica Shen, Shichun Lun, et al.
Anesthesia and Analgesia
|
July 18, 2008
Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor
Camilo Rojas, Marigo Stathis, Ajit G Thomas, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
April 13, 2023
Dendrimer-enabled targeted delivery attenuates glutamate excitotoxicity and improves motor function in a rabbit model of cerebral palsy
Fan Zhang, Zhi Zhang, Jesse Alt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2019
Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine
Sabrina Z Wang, Brad Poore, Jesse Alt, et al.
Journal of Medicinal Chemistry
|
November 16, 2012
Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors
Krupa Shukla, Dana V Ferraris, Ajit G Thomas, et al.
Current Drug Metabolism
|
September 7, 2021
Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement
Jesse Alt, Sadakatali S Gori, Kathryn M Lemberg, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 78) with videos related to
Sort By:
Page
of 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 26, 2023
Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
Bachchu Lal, Aditya Kulkarni, Joseph McDermott, et al.
Scientific Reports
|
May 24, 2018
The Diversity of Chemoprotective Glucosinolates in Moringaceae (Moringa spp.)
Jed W Fahey, Mark E Olson, Katherine K Stephenson, et al.
Journal of Medicinal Chemistry
|
March 21, 2019
Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs
Lukáš Tenora, Jesse Alt, Ranjeet P Dash, et al.
Theranostics
|
June 3, 2020
Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome
Elizabeth Smith Khoury, Anjali Sharma, Rajasekhar R Ramireddy, et al.
Nature Communications
|
November 17, 2023
Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis
Sadiya Parveen, Jessica Shen, Shichun Lun, et al.
Anesthesia and Analgesia
|
July 18, 2008
Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor
Camilo Rojas, Marigo Stathis, Ajit G Thomas, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
April 13, 2023
Dendrimer-enabled targeted delivery attenuates glutamate excitotoxicity and improves motor function in a rabbit model of cerebral palsy
Fan Zhang, Zhi Zhang, Jesse Alt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2019
Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine
Sabrina Z Wang, Brad Poore, Jesse Alt, et al.
Journal of Medicinal Chemistry
|
November 16, 2012
Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors
Krupa Shukla, Dana V Ferraris, Ajit G Thomas, et al.
Current Drug Metabolism
|
September 7, 2021
Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement
Jesse Alt, Sadakatali S Gori, Kathryn M Lemberg, et al.
Page
of 8